Tavapadon Shows Significant Promise for Newly Diagnosed Parkinson's Disease

Results from the Phase 3 TEMPO-2 trial, published in The Lancet Neurology in August 2026, indicate that tavapadon, a selective D1/D5 dopamine agonist, significantly improved motor symptoms and activities of daily living scores in patients with newly diagnosed Parkinson's disease. This marks a significant development, as an FDA application for early monotherapy other than levodopa, based on a positive pivotal trial, has not been received in decades.